Mankind Pharma Moat Analysis: Score & Risks
Mankind Pharma Ltd.
A first-pass moat teardown of Mankind Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Mankind Pharma Ltd. scores 5.23 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Our pan-India market and distribution network is one of the largest, helping us to make our products affordable as well as accessible to customers in different parts of the country.”
“It is vertically integrated through in-house cell lines”
“Through in-licensing partnerships with global pharma leaders, we have introduced niche and complex products like Neptaz, Nobeglar, Symbicort and Crenzlo, boasting our offerings in the specialty chronic category.”
“Ranked #1/#2 in 9 key brand families1 with limited competition in India”
“This product is priced above INR1 lakh per injection and is positioned as one of the most premium products across our portfolio.”
“Symbicort - Exclusive distribution agreement with AstraZeneca for India, marking our entry into the premium inhalation segment.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion